PRCT
PROCEPT BioRobotics Corporation
NASDAQ · Healthcare · Medical - Devices · US
$22.76
+6.50%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 337.3M | 308.1M | 224.5M | 136.2M | 75.0M |
| Cost of Revenue | 122.3M | 111.8M | 87.4M | 65.1M | 37.9M |
| Gross Profit | 215.0M | 196.2M | 137.1M | 71.0M | 37.1M |
| Operating Expenses | |||||
| R&D Expense | 77.2M | 71.3M | 62.3M | 48.4M | 29.0M |
| SG&A Expense | 252.1M | 228.8M | 171.4M | 131.8M | 88.8M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 1.00 | — | — | — | — |
| Total Operating Expenses | 329.3M | 300.1M | 233.7M | 180.2M | 117.8M |
| Cost and Expenses | 451.6M | 411.9M | 321.1M | 245.4M | 155.7M |
| Operating Income (EBIT) | (114.2M) | (103.9M) | (96.6M) | (109.2M) | (80.7M) |
| Non-Operating | |||||
| Interest Income | 8.3M | 12.2M | 10.9M | 7.6M | 2.5M |
| Interest Expense | 3.5M | 3.6M | 4.2M | 4.0M | 5.2M |
| Net Interest Income | 4.9M | 8.6M | 6.7M | 3.6M | (2.7M) |
| Other Non-Op Income/Expense | 4.8M | 8.5M | 5.2M | 3.3M | (6.4M) |
| Non-Operating Income (excl Interest) | (8.2M) | (12.1M) | (9.4M) | (7.3M) | 1.2M |
| EBT (Pre-Tax Income) | (109.5M) | (95.4M) | (91.4M) | (105.9M) | (87.2M) |
| Income Tax Expense | 284.0K | 190.0K | — | — | — |
| Bottom Line | |||||
| Net Income | (109.8M) | (95.6M) | (91.4M) | (105.9M) | (87.2M) |
| Earnings from Cont. Ops | (109.8M) | (95.6M) | (91.4M) | (105.9M) | (87.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (109.8M) | (95.6M) | (91.4M) | (105.9M) | (87.2M) |
| Per Share | |||||
| Basic EPS | ($1.94) | ($1.72) | ($1.75) | ($2.24) | ($1.96) |
| Diluted EPS | ($1.94) | ($1.72) | ($1.75) | ($2.24) | ($1.96) |
| Revenue Per Share | $5.97 | $5.55 | $4.31 | $2.88 | $1.69 |
| Shares | |||||
| Basic Shares Outstanding | 56.5M | 55.5M | 52.1M | 47.3M | 44.4M |
| Diluted Shares Outstanding | 56.5M | 55.5M | 52.1M | 47.3M | 44.4M |
| Profitability Metrics | |||||
| EBITDA | (98.9M) | (85.4M) | (82.0M) | (98.1M) | (79.1M) |
| D&A | 7.1M | 6.4M | 5.2M | 3.8M | 2.8M |
| EBIT | (106.0M) | (91.8M) | (87.2M) | (101.9M) | (82.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026